The American Diabetes Association (ADA) is having its 69th Scientific Sessions this week. The conference began on June 5 and will run until June 9. I'm eager to see what types of advances will be revealed this year. The ADA is also using Twitter to post updates, but I don't see many people following @AmDiabetesAssn or @SciSessions2009. Do you use Twitter? Follow @DrJosephKim to all my updates.
Some of the hot issues seem to focus on:
- Using HbA1c to diagnose diabetes. How often do you check HbA1c in patients who don't have diabetes? Some are using that test to screen patients for elevated glucose levels. Is that warranted? Is there a role for using HbA1c to diagnose diabetes? Is the HbA1c better than a fasting glucose test or the glucose tolerance test?
- Final results from the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) study. Rosiglitazone (Avandia) may increase heart failure, but does it increase mortality? The answer appears to be "no."